Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aram F Hezel

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
Journal of the American Society of Nephrology : JASN|November 9, 2017
Serum Response Factor Is Essential for Maintenance of Podocyte Structure and FunctionBing Guo, Qing Lyu, Orazio J Slivano, et al.
Cancer Research|June 7, 2018
<i>Kras</i> and <i>Tp53</i> Mutations Cause Cholangiocyte- and Hepatocyte-Derived CholangiocarcinomaMargaret A Hill, William B Alexander, Bing Guo, et al.
Cancer Research|July 13, 2012
TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progressionAram F Hezel, Vikram Deshpande, Stephanie M Zimmerman, et al.
Clinical Colorectal Cancer|May 16, 2020
Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution ExperienceFranklin Li, Gradon Nielsen, Andrea Baran, et al.
Genes & Development|November 23, 2006
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancerNabeel Bardeesy, Kuang-Hung Cheng, Justin H Berger, et al.
Cancer Research|January 24, 2012
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinomaMichael R O'Dell, Jing Li Huang, Christa L Whitney-Miller, et al.
Cancer|April 2, 2015
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)Ramesh K Ramanathan, Shannon L McDonough, Hagen F Kennecke, et al.
Advances in Radiation Oncology|August 12, 2017
Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinomaMostafa Mohamed, Alan W Katz, Mohamedtaki A Tejani, et al.
Human Pathology|February 2, 2024
SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma: Clinicopathologic and immunohistochemical studyIrene Y Chen, Mark G Ettel, Phoenix D Bell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancerBrian M Wolpin, Aram F Hezel, Thomas Abrams, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Journal of the American Society of Nephrology : JASN|November 9, 2017
Serum Response Factor Is Essential for Maintenance of Podocyte Structure and FunctionBing Guo, Qing Lyu, Orazio J Slivano, et al.
Cancer Research|June 7, 2018
<i>Kras</i> and <i>Tp53</i> Mutations Cause Cholangiocyte- and Hepatocyte-Derived CholangiocarcinomaMargaret A Hill, William B Alexander, Bing Guo, et al.
Cancer Research|July 13, 2012
TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progressionAram F Hezel, Vikram Deshpande, Stephanie M Zimmerman, et al.
Clinical Colorectal Cancer|May 16, 2020
Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution ExperienceFranklin Li, Gradon Nielsen, Andrea Baran, et al.
Genes & Development|November 23, 2006
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancerNabeel Bardeesy, Kuang-Hung Cheng, Justin H Berger, et al.
Cancer Research|January 24, 2012
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinomaMichael R O'Dell, Jing Li Huang, Christa L Whitney-Miller, et al.
Cancer|April 2, 2015
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)Ramesh K Ramanathan, Shannon L McDonough, Hagen F Kennecke, et al.
Advances in Radiation Oncology|August 12, 2017
Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinomaMostafa Mohamed, Alan W Katz, Mohamedtaki A Tejani, et al.
Human Pathology|February 2, 2024
SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma: Clinicopathologic and immunohistochemical studyIrene Y Chen, Mark G Ettel, Phoenix D Bell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancerBrian M Wolpin, Aram F Hezel, Thomas Abrams, et al.
Pageof 7